Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients

  • Solé Font, Laura|||0000-0002-3195-0565
  • Lobo-Jarne, Teresa|||0000-0002-1632-438X
  • Cabré-Romans, Júlia-Jié
  • González, Antón
  • Fernández, Lierni
  • Marruecos, Laura|||0000-0002-4206-709X
  • Guix, Marta|||0000-0002-2143-0697
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • López, Sandra
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Torres, Ferran|||0000-0002-7355-7913
  • Iglesias, Mar|||0000-0002-2274-4671
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Espinosa, Lluis|||0000-0002-2897-4099
Background: We have previously shown that non-curative chemotherapy imposes fetal conversion and high metastatic capacity to cancer cells. From the set of genes differentially expressed in Chemotherapy Resistant Cells, we obtained a characteristic fetal intestinal cell signature that is present in a group of untreated tumors and is sufficient to predict patient prognosis. A feature of this fetal signature is the loss of CDX1. Methods: We have analyzed transcriptomic data in public datasets and performed immunohistochemistry analysis of paraffin embedded tumor samples from two cohorts of colorectal cancer patients. Results: We demonstrated that low levels of CDX1 are sufficient to identify patients with poorest outcome at the early tumor stages II and III. Presence tumor areas that are negative for CDX1 staining in stage I cancers is associated with tumor relapse. Conclusions: Our results reveal the actual possibility of incorporating CDX1 immunostaining as a valuable biomarker for CRC patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis

  • Solé Font, Laura|||0000-0002-3195-0565
  • Lobo-Jarne, Teresa|||0000-0002-1632-438X
  • Álvarez-Villanueva, Daniel
  • Alonso-Marañón, Josune
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Guix, Marta|||0000-0002-2143-0697
  • Sangrador, Irene
  • Rozalén, Catalina
  • Vert, Anna
  • Barbachano, Antonio|||0000-0002-1248-5143
  • Lop Gros, Joan|||0000-0002-9442-5688
  • Salido, Marta|||0000-0001-9988-5977
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • García-Romero, Raquel
  • Garrido, Marta
  • González Miranda, Jessica|||0000-0001-7732-1564
  • Martínez-Iniesta, María
  • López-Arribillaga, Erika|||0000-0002-9451-6635
  • Salazar, Ramón
  • Torres, Ferran|||0000-0002-7355-7913
  • Iglesias, Mar|||0000-0002-2274-4671
  • Celià-Terrassa, Toni|||0000-0002-0615-8744
  • Muñoz, Alberto|||0000-0003-3890-4251
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Espinosa, Lluis|||0000-0002-2897-4099
Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and patient outcome is primarily unstudied. Using CRC patient-derived organoids (PDO)s, we show that sublethal doses of chemotherapy (CT) does not select previously resistant tumor populations but induces a quiescent state specifically to TP53 wildtype (WT) cancer cells, which is linked to the acquisition of a YAP1-dependent fetal phenotype. Cells displaying this phenotype exhibit high tumor-initiating and metastatic activity. Nuclear YAP1 and fetal traits are present in a proportion of tumors at diagnosis and predict poor prognosis in patients carrying TP53 WT CRC tumors. We provide data indicating the higher efficacy of CT together with YAP1 inhibitors for eradication of therapy resistant TP53 WT cancer cells. Together these results identify fetal conversion as a useful biomarker for patient prognosis and therapy prescription.